Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
8.23 K
Value Traded
53.43 K
Short % Float
0.45%
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
464.94 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
71.80 M
Float Shares
18.45 M
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SVA Catalyst Timeline
Dated clinical, regulatory and corporate events for Sinovac Biotech, Ltd
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sinovac Biotech, Ltd
767Total events
2Upcoming
183Tier-1 (high impact)
2004 to 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T3WHO Prequalification
Subscribe to view catalyst details
Event history 50
▲FDA Filing AcceptedHFMD2FiledRegulatory Filing
HFMD2 NDA accepted for review by CDE
hand, foot and mouth diseasesource ↗
▲Priority Review DesignationHFMD2FiledDesignation
HFMD2 granted priority review designation
hand, foot and mouth diseasesource ↗
●Timing GuidancePCV13Presentation
PCV13 NDA submission expected in Q3 2026
pneumococcal diseasesource ↗
●Quarterly UpdateCorporate
Unaudited and unreviewed second half of 2025 financial results reported
◆FDA Filing AcceptedRegulatory Filing
Requested hearing before Nasdaq Panel to appeal delist determination
▼FDA Filing AcceptedRegulatory Filing
Received delist determination letter from Nasdaq for failure to file 2025 annual report on Form 20-F
▲FDA Filing AcceptedRegulatory Filing
Completed filings of 2024 annual report and interim balance sheet/income statement by May 11, 2026 deadline
▲FDA Filing AcceptedRegulatory Filing
Regained compliance with Nasdaq Periodic Filing Rule as of May 8, 2026
▲FDA Feedback ReceivedFDA Meeting
Nasdaq Hearings Panel grants continued listing subject to conditions
◆Management ChangeCorporate
Nasdaq Hearings Panel hearing scheduled to appeal delisting determination
◆Restructuring LayoffsCorporate
Nasdaq Hearings Panel hearing to appeal delisting determination and address late filing
▼Quarterly UpdateCorporate
Received Nasdaq notification for late filing of 2025 half-year report
●Quarterly UpdateCorporate
Antigua High Court interim order gives board control until trial of disputed 2025 shareholder meeting
◆Restructuring LayoffsCorporate
Deadline to request hearing to appeal delisting determination
▼Stock ListingCorporate
Received Nasdaq delisting determination letter for failure to file 2024 Annual Report
◆Quarterly UpdateCorporate
Special Meeting of Shareholders to vote on board removal and appointment
◆IP Litigation RulingIP / Competition
Eastern Caribbean Court of Appeal granted temporary stay of injunction
◆Quarterly UpdateCorporate
Special Meeting of Shareholders to vote on director removal and election
◆IP Litigation RulingIP / Competition
Antigua Court granted interim injunction prohibiting PIPE shares from voting at Special Meeting
▼Quarterly UpdateCorporate
Received Nasdaq notification for late filing of 2024 Annual Report
▲Other Regulator MilestoneEx-US Regulatory
Privy Council Order received implementing Judgment on board election and poison pill invalidation
◆IP Litigation RulingIP / Competition
Privy Council ruled that 2018 AGM shareholder slate was rightfully elected Board and Rights Agreement invalid
◆IP Litigation RulingIP / Competition
Motion to dismiss hearing in MW Gestion class action scheduled for September 4, 2024
◆IP Litigation RulingIP / Competition
Privy Council hearing on 1Globe appeal (July 10-11, 2024); judgment reserved
◆IP Litigation RulingIP / Competition
Privy Council substantive hearing listed for July 10-11, 2024 in 1Globe appeal
●Quarterly UpdateCorporate
Reported unaudited financial results for second half of 2023 and filed 2023 annual report on Form 20-F
◆Topline ReadoutSA55Clinical Data
Preliminary results from phase II trial of SA55 Injection anticipated by year's end
COVID-19 infectionsource ↗
▲Trial CompletionSA55Trial
Phase I clinical trial completed for SA55 Injection
COVID-19 infectionsource ↗
▲First Patient DosedSA55Trial
First participant enrolled in phase II trial of SA55 Injection
COVID-19 infectionsource ↗
▲Other Regulator MilestoneHealiveApprovedEx-US Regulatory
Healive received market approvals in Lebanon, Kyrgyzstan, Egypt, India and Pakistan in 2023
Hepatitis Asource ↗
▲Manufacturing MilestoneCMC / Inspection
New influenza vaccine production line started operations in Beijing
Influenzasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Influenza vaccines gained overseas market approvals in Pakistan and Chile in first half of 2023
Influenzasource ↗
▲IND ClearanceIND
Bivalent inactivated vaccine for EV and CV infections approved for clinical trials in China
Hand, foot and mouth disease (EV71 and CA16)source ↗
Past FDA Catalysts and PDUFA Decisions
How SVA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | 13-valent pneumococcal conjugate vaccine (PCV13) | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
19
Drugs Scored
rNPV / MCap
Top Drug
Top 9%
Micro Cap(rank 60 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactivated Hepatitis A Vaccine VaccineNCT07793227 | Hepatitis A Vaccine | Phase 3 | RECRUITING | 680 | Sep 15, 2027 | ||||||
| PROVARIX Monoclonal antibodyNCT07475000 | Varicella (Chickenpox) | Phase 3 | RECRUITING | 300 | Nov 15, 2026 | ||||||
| Sinovac PCV13 lot 1 Monoclonal antibodyNCT07832500 | Pneumococcal Infectious Diseases | Phase 3 | NOT YET_RECRUITING | 1,125 | Mar 1, 2027 | ||||||
| Cell-based Trivalent Split Influenza Virus Vaccine VaccineNCT07889193 | Seasonal Influenza | Phase 1 | NOT YET_RECRUITING | 175 | May 1, 2027 | ||||||
| RSV mRNA vaccine VaccineNCT07418229 | RSV | Phase 1 | NOT YET_RECRUITING | 60 | May 30, 2027 | ||||||
| Group ACYW135X Meningococcal Conjugate Vaccine VaccineNCT07374510 | Meningococcal Meningitis | Phase 1 | NOT YET_RECRUITING | 150 | Nov 30, 2026 | ||||||
| low dose Bivalent Enterovirus Vaccine, Inactivated VaccineNCT06734832 | Hand, Foot, and Mouth Disease（HFMD) | Phase 3 | RECRUITING | 8,000 | Nov 30, 2026 | ||||||
| COVID-19 Vaccine, Inactivated, Omicron Strain VaccineCompletedNCT05411471 | COVID-19 | Phase 3 | COMPLETED | 2,971 | Jun 25, 2023 | ||||||
| Influenza Vaccine, Inactivated VaccineCompletedNCT05431725 | Seasonal Influenza | Phase 3 | COMPLETED | 2,202 | Jul 19, 2023 | ||||||
| Influenza Vaccine, Inactivated VaccineCompletedNCT07737106 | Influenza | Phase 1 | COMPLETED | 50 | Feb 24, 2026 | ||||||
| Investigational tetanus vaccine, adsorbed VaccineCompletedNCT06049940 | Tetanus | Phase 3 | COMPLETED | 1,260 | Mar 22, 2024 | ||||||
| SNA02-48 Monoclonal antibodyNCT06939777 | Tetanus | Phase 3 | COMPLETED | 855 | Mar 30, 2026 | ||||||
| Sabin Strain Inactivated Poliovirus Vaccine VaccineCompletedNCT05850364 | Poliomyelitis | Phase 3 | COMPLETED | 1,442 | Feb 13, 2025 | ||||||
| Sinovac PCV24 Monoclonal antibodyNCT06550830 | Pneumococcal Infectious Disease | Phase 3 | COMPLETED | 4,609 | Jun 25, 2025 | ||||||
| hexavalent reassortant rotavirus attenuated live vaccine VaccineNCT06950645 | Rotavirus Gastroenteritis | Phase 2 | COMPLETED | 500 | Dec 18, 2025 | ||||||
| Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 VaccineCompletedNCT04383574 | COVID-19 | Phase 1 | COMPLETED | 974 | May 31, 2022 | ||||||
| Sinovac Low-dosage PCV24 Monoclonal antibodyCompletedNCT07543198 | Pneumococcal Infectious Disease | Phase 1 | COMPLETED | 385 | Feb 26, 2026 | ||||||
| Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine VaccineCompletedNCT05092386 | Pneumococcal Infections | Phase 1 | COMPLETED | 310 | May 28, 2024 | ||||||
| low dose Bivalent Enterovirus Vaccine, Inactivated VaccineCompletedNCT06063057 | Hand, Foot and Mouth Disease | Phase 1 | COMPLETED | 744 | Mar 10, 2026 | ||||||
| Quadrivalent influenza vaccine (split virion), inactivated VaccineMarketedNCT07211152 | Influenza | Phase 3 | COMPLETED | 150 | Jun 26, 2026 | ||||||
| Sinovac rabies vaccine VaccineNCT07357545 | Rabies | Phase 3 | COMPLETED | 2,952 | Jun 21, 2023 | ||||||
| Low-dose of tetravalent inactivated enterovirus vaccine VaccineNCT06754384 | Hand, Foot, and Mouth Disease(HFMD) | Phase 3 | COMPLETED | 6,552 | Feb 10, 2026 | ||||||
| SARS-CoV-2 vaccine VaccineMarketedNCT04508075 | SARS-CoV2 Infection | Phase 3 | COMPLETED | 1,620 | Aug 31, 2021 | ||||||
| Varicella Vaccine VaccineMarketedNCT06314724 | Varicella | Phase 3 | COMPLETED | 942 | Sep 6, 2024 | ||||||
| Inactivated COVID-19 Vaccine VaccineMarketedNCT04992260 | COVID-19 | Phase 3 | COMPLETED | 11,349 | May 31, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every SVA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sIPV | Polio | Phase 3 | 2019-04-16 | seroconversion rate type 1: 98.0%; seroconversion rate type 2: 94.8%; seroconversion rate type 3: 98.9%; ipv seroconversion rate type 1: 94.1%; ipv seroconversion rate type 2: 84.0%; ipv seroconversion rate type 3: 97.7%Read More | Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease The Sinovac-developed sIPV demonstrates both long-term afforRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SVA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SVA for Q2 2026. | ||||
SVA Institutional Ownership Trends
SVA Short Interest
Shares sold short, counted twice a month.
0.45%
Short % of Float
of tradable shares sold short
82.2K
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
0
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SVA ranks across every disease it competes in
Competitive Position is a premium feature
See how SVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSVA News
-SVA
Aug 17, 2026SINOVAC Reports Unaudited First Half of 2026 Financial Results
Sinovac Biotech Ltd. has announced its unaudited financial results for the first half of 2026. The results have been filed with the U.S. Securities and Exchange Commission and are accessible online. The company continues to position itself as a leading biopharmaceutical provider in China.
Read more →-SVA
Jul 15, 2026SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Sinovac Biotech Ltd. has announced an extension for shareholders to submit payment instructions for its special cash dividend. The dividend, set at $55.00 per common share, is aimed at rewarding valid holders of the company's shares. This extension reflects the company's commitment to its shareholders.
Read more →-SVA
Jun 15, 2026SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
SINOVAC has regained compliance with the Nasdaq Global Market's listing requirements, indicating a positive step for the company. This compliance suggests that SINOVAC has met the necessary financial and operational standards set by Nasdaq. The news may impact investor confidence and market perception positively.
Read more →-SVA
Jun 5, 2026SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
SINOVAC has reported its unaudited and unreviewed financial results for the second half of 2025. The company has also filed its 2025 Annual Report on Form 20-F. However, the unaudited nature of the results may raise concerns among investors regarding the reliability of the financial data.
Read more →-SVA
May 29, 2026SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
SINOVAC has been notified by Nasdaq about the late filing of its 2025 Annual Report. This notification indicates potential compliance issues that may affect the company's standing on the exchange. Investors may view this delay as a negative signal regarding the company's financial reporting practices.
Read more →-SVA
May 8, 2026SINOVAC Reports Unaudited First Half of 2025 Financial Results
SINOVAC has reported its unaudited financial results for the first half of 2025. The report lacks detailed insights, leading to concerns about the company's financial health. Investors may find the absence of comprehensive data troubling as it could impact future business decisions.
Read more →-SVA
Apr 30, 2026SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. has filed its annual report on Form 20-F for the fiscal year 2024 with the SEC. The report highlights the company's extensive portfolio of vaccines and its commitment to combating infectious diseases. Sinovac continues to innovate and expand its global presence, aiming to enhance vaccine development and accessibility.
Read more →-SVA
Jan 22, 2026SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Sinovac Biotech Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon meeting specific financial filing requirements by May 11, 2026. The company is collaborating with Zhonghua Certified Public Accountants LLP to ensure compliance with Nasdaq rules and complete necessary audits. Sinovac remains focused on maintaining its commitment to regulatory obligations.
Read more →-SVA
Jan 5, 2026Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac Biotech Ltd. has received a notification from Nasdaq regarding its late filing of the 2025 half-year report. The company is scheduled to present its case to the Nasdaq Hearings Panel on January 8, 2026, in an effort to maintain its listing. This follows a previous delisting determination received in November 2025.
Read more →-SVA
Jan 2, 2026Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025
Sinovac Biotech Ltd. has received a notification from Nasdaq indicating that it failed to comply with its Listing Rule regarding timely filing. This notification follows a previous delisting determination that the company is contesting at a scheduled hearing. Sinovac is preparing to present its views to the Nasdaq Hearings Panel in hopes of maintaining its listing. The company has a history of providing biopharmaceutical products and vaccines in China.
Read more →-SVA
Dec 17, 2025Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
Sinovac Biotech Ltd. announced that the Antigua High Court has granted control of the company’s board to its current members until a trial regarding a disputed shareholder meeting takes place in late April or early May 2026. The decision follows a hearing related to the composition of the board during an ongoing dispute. In a recent board meeting, the directors reaffirmed their commitment to enhancing shareholder value and stability while addressing current challenges, including restoring NASDAQ trading for their shares. Sinovac continues to focus on its mission to supply vaccines and improve health outcomes globally.
Read more →-SVA
Nov 18, 2025SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
Sinovac Biotech Ltd. has announced that it received a delisting notice from Nasdaq due to its failure to file the 2024 Annual Report by the deadline. The company intends to appeal this decision, requesting a hearing before the Nasdaq Hearing Panel as it seeks to regain compliance with the listing requirements. The appeal process will temporarily halt the suspension of its securities. Sinovac is currently collaborating with a new accounting firm to expedite the filing of required reports.
Read more →-SVA
Oct 24, 2025SINOVAC Announces Appointment of Independent
SINOVAC Biotech Ltd. (NASDAQ: SVA) has appointed UHY LLP as its independent auditor, starting from October 24, 2025. The appointment aims to enhance financial oversight and ensure compliance with SEC and NASDAQ requirements. UHY will oversee the audits of SINOVAC's financial statements for several years, including internal controls. The company emphasizes the importance of transparency in conjunction with its ongoing business goals and potential trading resumption on NASDAQ.
Read more →-SVA
Jul 10, 2025SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
SINOVAC Biotech's Board of Directors has strongly rejected claims made by SAIF and the former board regarding a Special Meeting of Shareholders. The Board asserts that the Special Meeting was validly adjourned pending a court decision on the validity of PIPE shares. They emphasize that the current Board remains the legitimate governing body and is committed to protecting shareholder interests amidst ongoing legal disputes. The company plans to pursue legal remedies against perceived unlawful actions taken by SAIF and the former board.
Read more →-SVA
Jul 10, 2025Elected Directors of Sinovac Hold the First Board Meeting Andrew Y. Yan elected Chairman of the Board
Sinovac Biotech Ltd. has announced that its newly elected board of directors held their first meeting, electing Andrew Y. Yan as Chairman. The board unanimously resolved to explore future dividend plans and seek a new auditor to facilitate the resumption of NASDAQ trading. They emphasized their commitment to restoring stable operations and resolving ongoing litigations with shareholders. The board also stated their support for the existing management team, highlighting a focus on enhancing transparency and shareholder trust.
Read more →-SVA
Jul 9, 2025SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares
SINOVAC Biotech Ltd. has announced the adjournment of its Special Meeting of Shareholders pending a court decision on the validity of certain PIPE shares, which were restricted from voting by a recent injunction. The situation arose from litigation in Antigua, where the former board's PIPE transaction is being challenged. A temporary stay from the Eastern Caribbean Court of Appeal allows for a limited ability for those shares to vote while legal proceedings continue. Meanwhile, SINOVAC is distributing a special cash dividend to shareholders, emphasizing its commitment to fairness and governance during this process.
Read more →-SVA
Jul 8, 2025Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
Institutional Shareholder Services Inc. (ISS) has aligned with Glass Lewis in advising Sinovac shareholders to retain the current board. This recommendation follows the board's efforts to improve shareholder value by instituting a significant dividend and working towards resuming trading of company shares. The current board has taken swift actions to rectify the governance failures of the previous board, which had a detrimental impact on shareholder value. The upcoming special meeting will allow shareholders to vote against the proposals to remove the current board.
Read more →-SVA
Jul 2, 2025Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place
Glass Lewis, a leading independent proxy advisory firm, has advised SINOVAC shareholders to vote to keep the current board in place ahead of the special meeting scheduled for July 2025. The advisory firm praised the board for demonstrating credible progress in governance and operational stability. In contrast, Glass Lewis criticized the proposals from the dissident group, citing concerns about their reliability and associations with past governance failures. SINOVAC's board is encouraging shareholders to reject the proposed changes to protect their investments.
Read more →-SVA
Jun 30, 2025SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card "AGAINST" the Misguided Proposals to Remove SINOVAC's Current Board
SINOVAC's Board of Directors urges shareholders to vote against proposals aimed at removing the current board at the upcoming Special Meeting on July 9, 2025. The board emphasizes its commitment to declare substantial cash dividends and protect shareholder interests amid ongoing legal challenges from a dissenting investor group. They argue that the previous board's actions drained resources and failed to provide dividends while stressing their efforts to restore compliance with NASDAQ and enhance shareholder value. The call to action highlights the importance of shareholder votes in determining the company's future direction and governance.
Read more →About Sinovac Biotech, Ltd
BIOPHARMAWATCH ELITE PLUS
Trade the next SVA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime